Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Table 3 Adverse outcomes of biosimilar switch leading to treatment discontinuation: originator vs biosimilars, n (%)

	Adalimumab originator (n = 43)	Idacio (MSB11022; n = 27)	Hadlima (SB5; n = 63)	Hulio (FKB327; n = 86)	Hyrimoz (GP2017; n = 48)	Amgevita (ABP 501;n = 4)	P value
Duration on biosimilar after switch (months ± SD)	-	26.0 ± 2.83	24.9 ± 5.32	22.3 ± 9.52	26.5 ± 4.64	26.3 ± 1.26	0.131
Discontinuation of adalimumab	7 (16.3)	2 (7.41)	4 (6.35)	19 (22.1)	2 (4.17)	0
Reason for discontinuation
Loss of response	2 (4.65)	1 (3.70)	1 (1.59)	12 (14.0)	0	0
Adverse events	2 (4.65)	0	3 (4.76)	5 (5.81)	2 (4.17)	0
Other patient factors	3 (6.98)	1 (3.70)	0	2 (2.33)	0	0